Sight Sciences, Inc. is an ophthalmic medical device company focused on developing innovative technologies to diagnose and treat eye conditions. Since its founding in 2011, the company has concentrated on ophthalmic solutions for ocular surface disease and glaucoma, combining engineering expertise with clinical research to address unmet needs in eye care.
The company’s flagship product, the TearCare® System, is designed to treat Meibomian Gland Dysfunction (MGD), a leading cause of evaporative dry eye disease. The system delivers controlled thermal energy to the eyelids and simultaneously applies natural gland expression, helping to restore gland function and improve tear film quality. In parallel, Sight Sciences is advancing a pipeline of diagnostic and therapeutic devices aimed at better managing glaucoma and other anterior segment disorders.
Headquartered in Menlo Park, California, Sight Sciences has established a U.S. commercial footprint and is pursuing international distribution through strategic partnerships. The company supports eye care professionals with training programs, clinical support, and ongoing education to facilitate the adoption of its technologies and to ensure optimal patient outcomes.
Under the leadership of Chief Executive Officer Keith Walter and a management team with extensive experience in ophthalmology and medical technology, Sight Sciences remains committed to driving clinical evidence and expanding its product portfolio. The company continues to invest in research and development, leveraging data from multicenter trials to advance its mission of improving the quality of life for patients with eye disease.
AI Generated. May Contain Errors.
Free SGHT Stock Alerts